




RNA as drug target: docking studies

Florent Barbault ITODYS CNRS (UMR7086) Univ. Paris7 Group of Molec. Modeling & Chem. Info.




Overview


- Why targeting RNA
- Drug design strategy
- Parametrisation of the scoring function
- First Virtual screening
- Flexibility of target
- Conclusions & Prospects

Why targeting RNA?

RNA and DNA are negatively charged molecules



DNA structures double strand => mainly Helix



Why targeting RNA?

Biological role of RNA:

- Protein synthesis (mRNA, Ribosome, tRNA)
- Enzyme (Ribozyme)
- RNA is the genome of all retrovirus (HIV, HCV,...)
- RNA can control gene regulation (siRNA)

We need new and original targets RNA can be one of them

RNA is involved in a lot of biological functions

Different opportunities and effects

RNA have structural domains that are more highly conserved Slower developpment of drug resistance


RNA is upstream in translation pathway (protein synthesis)

Inhibiting 1 RNA (ribosome) could prevent ~1000 proteins

Drug-design strategy

Purpose: design antimicrobial compounds

Protein synthesis scheme



Same global scheme for procaryote & eucaryote but 2 different RNA ribosomal fragments:

RNA 16S (bacteria) RNA 18S (human)


We want to design selective ligands against 16S and not 18S

Drug-design strategy

RNA ligands?

Aminoglycosides!

- Natural products
- Good affinity
- Low selectivity
- Ammonium groups
- Difficult to synthetize
- Flexible molecules




Goal:

- Take these molecules as scaffold for chemical modifications
- Add a nucleoside to make a triple-base-pair or intercalation

Drug-design strategy

Two questions:

		List of compounds with bioactivity?			
et?		YES	NO		
3D structure of the target?	YES	AII	Docking		
	NO	QSAR-2D QSAR-3D Pharmacophoric screening	NOTHING		



Autodock (3.0) pre-calculate energy grid maps: 1 for each atoms + electrostatic Ligands are flexible whereas target is rigid Genetic Algorithm + Local Search to find ligand position

$$\Delta G = \frac{f_{vdw}}{\sum} \left(\frac{A_{ij}}{r_{ij}^{12}} - \frac{B_{ij}}{r_{ij}^{6}} \right) + \frac{f_{hbond}}{\sum} E(t) \left(\frac{A_{ij}}{r_{ij}^{12}} - \frac{B_{ij}}{r_{ij}^{10}} \right) + E_{Hbond} \right] + \frac{f_{elec}}{\sum} \left(\frac{q_{i}q_{j}}{\epsilon(r_{ij})r_{ij}} \right) + \Delta G_{tors} N_{tors} + \frac{f_{solv}}{\sum} \left(S_{i}V_{j} + S_{j}V_{i} \right) e^{-r_{ij}^{2}}$$

5 empirical parameters derived from protein/ligand complexes

NOT SUITABLE TO RNA! We need these 5 parameters for RNA

We need RNA/Ligands structures with experimental ΔG

ONLY8!

Tobramycin with RNA aptamer I
Tobramycin with RNA aptamer II
Neomycin-B with RNA Tau exon
Neomycin-B with RNA aptamer
Neomycin-B with RNA HIV-1 Tar
Gentamicin C1A with A-site rRNA
Paramomycin with RNA-16S
Acetylpromazine with RNA HIV-1 Tar

aminoglycosides

For each structures:

31 docking calculations with differents parameters. Values are ranged from 0 to 2x of their default value. At the end: 248 results


Correct docking:

Free energy of binding similar to the experimental RMSD between experimental and calculated is low

ANN is used to correlate △G and RMSD with parameters.

1 hidden layers
Back propagation algorithm
Leave-One-Out cross-validation

Final RMS error: 0.269 and Final max error: 0.883




With the Neural Network Model

- 80,000 parameters were randomly generated and tested
- Best values were selected as good as possible ∆G agreement as weak as possible RMSD value

	Vdw	Elec	Hbond	Tors	Sol
Autodock	0.1485	0.1146	0.0656	0.3113	0.1711
RNA-Autodock	0.155	0.101	0.056	0.361	0.153

NeomycinB with RNA Tau 10




White: experimental

Blue: autodock

Red: RNA-autodock







White: experimental

Blue: autodock

Red: RNA-autodock





With the new scoring function: First Virtual Screening with ~300 compounds against 16S Library created in agreement with the organic chemist group

40 compounds were proposed for the synthesis 25 were synthesize (not only belonging to the 40) 17 present micromolar affinity (16&18S) & 8 no interaction.

Back docking calculation with Autodock for 16S & 18S:

- Understand selectivity
- Find Structure/Activity Relationships


Results:

- All ligands without interaction are placed at the end
- Except Neamine (bad pose?)
- Correlation between AG calculated and experimental
- R2= 0.72 for RNA-16S and R2=0.7 for RNA-18S

But:

- Unable to explain selectivity of 16S vs 18S
- Unable to find a 3rd base-pair or intercalation

TARGET FLEXIBILITY



After a first docking with RNA as rigid target:

Small Molecular Dynamic simulations with GB implicit solvent (AMBER 8.0)


MD of complexes (~2 hours for each complexes)


MD of target alone (~2 hours)

MD of Ligands alone (~5 minutes for each ligands)


Einteraction = Ecomplex - Etarget - Eligand

Force-fields: parm03 for RNA and gaff for Ligands






Graphical analysis



Graphical analysis



MD permit the adaptation of the target to form a triple base-pair

Conclusions & prospects

Conclusions:

- Design of a specific set of parameters for the scoring function
- Docking is able to discriminate "good" or "bad" ligands
- Docking is limited for RNA because of induced fit
- MD can predict more efficiently free energy of binding
- MD is able to remove "false" docking position
- MD need big computation times not yet applicable for VS

Prospects:

- Finish calculation for RNA 18S
- Extract structure activity relationships
- Limiting MD computation times with SA with restraint?

Aknowledgements



Peking University CHINA, Health science center 引に京大学 医学部 Pr. Lihe Zhang, Pr. Liangren Zhang & PhD Ron Bo

ITODYS, CNRS UMR 7086 University Paris7 FRANCE **Group of Molecular Modeling & Chemical Information**



Thank you for your attention